PRMT5 and lung carcinoma: High levels of PRMT5 expression in lung cancer have been associated with poor prognosis, and inhibition of PRMT5 can affect the growth cycle of lung cancer cells by inhibiting the phosphorylation of AKT1 [12, 15].